South America
Auris Medical Holding Ltd. announced that it has received written notification from the Nasdaq Hearings Panel notifying the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550 for continued listing on The Nasdaq Capital Market.
Auris Medical Holding Ltd. announced today the closing of its previously announced underwritten public offering
Auris Medical Holding Ltd. today announced the successful closing of the purchase of two US patents related to the use of betahistine for the treatment of depression and attention-deficit / hyperactivity disorder (ADHD).
Auris Medical Holding Ltd. announced the pricing of an underwritten public offering of: (i) 330,000 common shares together with warrants to purchase 330,000 common shares, and (ii) 1,721,280 pre-funded warrants, with each pre-funded warrant exercisable for one common share, together with warrants to purchase 1,721,280 common shares.
Auris Medical Holding Ltd. announced that it has reached the midpoint for enrollment in its Phase 1b proof-of-concept trial of AM-201, the Company’s investigational drug for the prevention of antipsychotic-induced weight gain and somnolence.
Auris Medical Holding Ltd. announced that its Board of Directors has approved a reverse stock split of its common shares at a ratio of 1-for-20.
Auris Medical Holding Ltd. provided an update on its tinnitus drug development strategy.
Auris Medical Holding Ltd. announced that the Nasdaq Hearings Panel has granted the Company’s request for the continued listing of the Company’s securities on The Nasdaq Capital Market.
Auris Medical Announces Randomization of First Dose Cohort in AM-201 Phase 1b Proof-of-Concept Study
Auris Medical Holding Ltd. announced that the first cohort of subjects have been randomized in its Phase 1b proof-of-concept trial of AM-201, the Company’s investigational drug for the prevention of antipsychotic-induced weight gain and somnolence.
Following international concern and outrage over a gene editing treatment of human embryos in China, the World Health Organization is taking action.
PRESS RELEASES